BioCryst Pharmaceuticals | Umsatzkosten

Aktienkurs
8.64
Täglich Wechseln
0.01 0.06%
Monatlich
28.88%
Jährlich
1.11%
Q1 Prognose
8.48




Umsatzkosten Veränderung Datum
Alnylam Pharmaceuticals USD 267.72M 67.57M 2025-12
BioCryst Pharmaceuticals USD 12.27M 9.04M 2024-12
Chugai Pharma JPY 87.56B 12.68B 2025-12
Daiichi Sankyo JPY 118.28B 37.7B 2025-12
Gilead Sciences USD 1.62B 50M 2025-12
GlaxoSmithKline GBP 2.61B 377M 2025-12
Glaxosmithkline GBP 3.01B 853.01M 2025-09
Incyte USD 121.18M 22.18M 2025-12
Ionis Pharmaceuticals USD 8M 5.66M 2025-12
Karyopharm Therapeutics USD 37.43M 2.41M 2024-09
Neurocrine Biosciences USD 17.6M 246.4M 2025-12
Novavax USD 60.62M 91.77M 2024-09
PTC Therapeutics USD 16.3M 7.02M 2025-12
Regeneron Pharmaceuticals USD 584.6M 63M 2025-12
Roche Holding CHF 8.48B 4.61B 2025-12
Sarepta Therapeutics USD 399.38M 247.93M 2025-12
Ultragenyx Pharmaceutical USD 29M 1.01M 2025-12
Vertex Pharmaceuticals USD 466M 51.2M 2025-12


BioCryst Pharmaceuticals Umsatzkosten - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Mar 2026.